TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06715683

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986278 Batched method, Dose A
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986278 Batched method, Dose A
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986278 Batched method, Dose A
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986278 Batched method, Dose A
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986278 Batched method, Dose B
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986278 Batched method, Dose B
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986278 Continuous method
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986278 Continuous method
Description: Specified dose on specified days
Study: NCT06704204

Intervention type: DRUG
Intervention: The first FDA-approved LAI ART regimen includes an integrase inhibitor, cabotegravir (CAB), and a non-nucleoside reverse transcriptase inhibitor, rilpivirine (RPV) combined 4 wks
Description: To date, there have been no studies looking at the use of LAI ART among justice involved PWH, yet a significant opportunity exists to improve HIV treatment outcomes in this high risk population.30
Study: NCT06745518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-172
Description: oral administration of TS-172 20\~60 mg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral administration of placebo
Study: NCT05974618

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound
Description: A standardised transvaginal (supplemented with transabdominal if transvaginal is not sufficient) examination is performed. When a colour Doppler ultrasound examination is performed, the pulse repetition frequency should be 0.3-0.6 KHz. The colour Doppler gain should be increased until colour Doppler artefacts appear and then lowered until just below the reappearance of colour Doppler artefacts. Ultrasound frequency and priority (grey scale or colour/Power Doppler) must also be optimised when using colour/power Doppler. Doppler ultrasound should be used with all masses included, irrespective of gestational age.

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound
Description: A standardised transvaginal (supplemented with transabdominal if transvaginal is not sufficient) examination is performed. When a colour Doppler ultrasound examination is performed, the pulse repetition frequency should be 0.3-0.6 KHz. The colour Doppler gain should be increased until colour Doppler artefacts appear and then lowered until just below the reappearance of colour Doppler artefacts. Ultrasound frequency and priority (grey scale or colour/Power Doppler) must also be optimised when using colour/power Doppler. Doppler ultrasound should be used with all masses included, irrespective of gestational age.

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound
Description: A standardised transvaginal (supplemented with transabdominal if transvaginal is not sufficient) examination is performed. When a colour Doppler ultrasound examination is performed, the pulse repetition frequency should be 0.3-0.6 KHz. The colour Doppler gain should be increased until colour Doppler artefacts appear and then lowered until just below the reappearance of colour Doppler artefacts. Ultrasound frequency and priority (grey scale or colour/Power Doppler) must also be optimised when using colour/power Doppler. Doppler ultrasound should be used with all masses included, irrespective of gestational age.
Study: NCT06761521

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Peri-Implantitis and Peri-implant mucositis
Description: peri-implant mucositis, peri-implantitis
Study: NCT06760637

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07220060
Description: CDK4 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole
Description: endocrine therapy
Study: NCT06355154

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional intervention
Description: The intervention will contain a diet with a reduced amount of carbohydrates compared to the standard treatment today but without caloric restriction.
Study: NCT04944953

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum Toxin Type A Injection [Botox]
Description: Single administration, Day 0, 20 units

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A injection [HG-102]
Description: Single administration, Day 0, 20 units
Study: NCT05324553

Intervention type: PROCEDURE
Intervention: Tissue Collection
Description: Research tissue specimen will be obtained during the patient's clinical biopsy or clinical tumor resection, if feasible.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood Collection
Description: Up to 50 mL of research blood will be drawn around the time of the procedure. Additional blood may be collected in selected cases, as warranted, to monitor disease recurrence/remission or perform additional

Intervention type: DIAGNOSTIC_TEST
Intervention: Buccal Swab
Description: Buccal swab may be requested, if necessary, to generate germline data.
Study: NCT06150430

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: APO
Description: Subjects will take part in 14 experimental sessions: two baseline sessions (T1-T2), three familiarization sessions (F1-F3), six training sessions (E1-E6), two assessment sessions (one pre-training T3 and one post training T4) and one 2-month follow-up session (T5). Depending on the session, the subject will walk with and/or without the APO. During the assessment sessions (T3-T4), the subject will be evaluated through different standard tests (such as 10MWTs and 2mWTs) and instrumented gait analysis, with and without the APO.~The goal of each training session (E1-E6) will be to achieve a minimum of 30 minutes of overground walking assisted by the APO, leaving up to 15 minutes to rest if needed. Training sessions will occur 2-3 times a week for 2-3 weeks to complete the training protocol.
Study: NCT04770350

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Focused Ultrasound
Description: The DWL Doppler ultrasound device enables visual and auditory waveform confirmation of the middle cerebral artery, and optical tracking technology (e.g., AntNeuro Visor2™ system) may be used in tandem with the Brainsonix ultrasound device to track a patient's brain in virtual space as well as their physical location, thereby ensuring accurate placement.
Study: NCT06208033

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SMET12
Description: 1. platinum-containing two-drug chemotherapy：Carboplatin plus Pemetrexed Disodium, administrated for 2-4 cycles, three weeks for one cycyles;Carboplatin 500mg/m2 d1,Pemetrexed Disodium AUV＝5 d1,Q3W;~2. Toripalimab, IV, 3mg/kg，Q2W；~3. SMET12: IV，60μg，Q2W，injected the day after toripalimab ；

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SMET12
Description: 1. platinum-containing two-drug chemotherapy：Carboplatin plus Pemetrexed Disodium, administrated for 2-4 cycles, 3 weeks for one cycle.cisplatin 75mg/m2 d1 Q3W,paclitaxel 100mg/m2 d1，d8，d15;~2. Toripalimab, IV, 3mg/kg，Q2W；~3. SMET12: IV，60μg，Q2W，injected the day after toripalimab ；

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SMET12
Description: 1. chemotherapy：Docetaxel 60-75 mg/m2 d1, administrated for 2-4 cycles, 3 weeks for one cycle.~2. Toripalimab, IV, 3mg/kg，Q2W；~3. SMET12: IV，60μg，Q2W，injected the day after toripalimab ；
Study: NCT06213272

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phono-Motor Therapy
Description: The goal of PMT is to build orthographic and phonological awareness and phonological sequence knowledge. During PMT, participants will complete a series of tasks manipulating minimal sound units (consonants (C) \& vowels (V)), combining these units into syllables (CVC, CVCC, CCVC) and syllable sequences (real words and readable nonwords). PMT will aim to engage 5 modalities: visual, acoustic, tactile kinesthetic, motor, and orthographic. Multisyllabic stimuli used during treatment will consist of 40 real words and 68 readable nonword letter strings.
Study: NCT05540405

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low-dose bitter melon
Description: Subject will receive 1 Insumate bitter melon capsule/d (300 mg) and 1 placebo capsule/d (300 mg)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High-dose bitter melon
Description: Subject will receive 2 Insumate bitter melon capsules/d (300 mg each)
Study: NCT06213272

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Phono-Motor Therapy
Description: The goal of PMT is to build orthographic and phonological awareness and phonological sequence knowledge. During PMT, participants will complete a series of tasks manipulating minimal sound units (consonants (C) \& vowels (V)), combining these units into syllables (CVC, CVCC, CCVC) and syllable sequences (real words and readable nonwords). PMT will aim to engage 5 modalities: visual, acoustic, tactile kinesthetic, motor, and orthographic. Multisyllabic stimuli used during treatment will consist of 40 real words and 68 readable nonword letter strings.
Study: NCT05540405

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subject will receive 2 placebo capsules/d (300 mg each)
Study: NCT06213272

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise Training (AET)
Description: Stationary ergometer cycling at 60% heart rate range for 20 minutes, plus 5 minutes of warm up and cool down.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stretching
Description: Light stretching activities targeting the head/neck, shoulder, elbow/forearm, hand/wrist, trunk/hip, ankle/foot.
Study: NCT05841797

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In-Person Program Management Plus (PM+)
Description: PM+ sessions conducted in-person by mentor mothers

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Program Management Plus (mHealth PM+)
Description: PM+ sessions conducted via phone
Study: NCT06304610

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: Questionnaire to probe socio-demographic data and information regarding sexual and reproductive health.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HPV self-sample
Description: Collection of HPV self-sample. The study nurse will explain step by step how the participant should take the test. The participant will also be given written instructions and the study nurse will always be around if the participant has any questions. The participant will be asked to take the self-sample in a private room with toilet. After collection the sample is handed back to the study nurse, who will then take the samples to the laboratory for analysis.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endocervical sample
Description: Endocervical sample taken by the gynaecologist. This procedure can be somewhat uncomfortable but not painful. The participant may always ask questions if she has any doubts or questions. The gynaecologist will perform the standard colposcopy examination after collection (for which the woman sits in the colposcopy waiting room)
Study: NCT06430671

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLS12311 low
Description: Peptide-coupled Red Blood Cells (RBCs)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLS12311 medium
Description: Peptide-coupled Red Blood Cells (RBCs)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLS12311 high
Description: Peptide-coupled Red Blood Cells (RBCs)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: uncoupled RBCs
Description: autologous Red Blood Cells (RBCs)
Study: NCT04888689

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Actimyo°
Description: Actimyo° is an innovative device intended to be used in a home-based environment. It is composed of two watch-like sensors, each containing a magneto-inertial sensors that record the linear acceleration, the angular velocity, the magnetic field of the movement in all directions.The two watches can be worn as wristwatch or placed near the ankle.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IMU
Description: IMU is a portable system of miniaturized inertial sensors for objective, instrumental, ambulatory, and validated analysis of normal and pathological human gait. Each miniaturized inertial sensor (2 cm × 0.7 cm × 0.5 cm) includes a triaxial accelerometer and a triaxial gyroscope.~These four inertial sensors are connected to a box by wires and are numbered 1 to 4. They must be attached - using adhesive tapes - on the participant's shoes.
Study: NCT06430671

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: uncoupled RBCs
Description: autologous Red Blood Cells (RBCs)
Study: NCT04938492

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for loneliness (CBT-L)
Description: 6 sessions focused on addressing thoughts, emotions, and behaviors that maintain feeling alone as a way to reduce loneliness and substance use.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Health Education Training (PHET)
Description: Health education provides information on the importance and benefits of and guidelines for living a healthy lifestyle.
Study: NCT05546268

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral MRT-2359
Description: Orally administered tablets of MRT-2359.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral MRT-2359
Description: Orally administered tablets of MRT-2359.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral MRT-2359
Description: Orally administered tablets of MRT-2359.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral MRT-2359
Description: Orally administered tablets of MRT-2359.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral MRT-2359
Description: Orally administered tablets of MRT-2359 in conjunction with intramuscular administration of fulvestrant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral MRT-2359
Description: Orally administered tablets of MRT-2359 in conjunction with orally administered enzalutamide.
Study: NCT04659863

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inclisiran
Description: Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL solution for subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile normal saline (0.9% sodium chloride in water for injection) for subcutaneous injection
Study: NCT06141850

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: COVID-19 Test Reporting
Description: Participants will use a simple text-based data reporting tool which they will be asked to use to report any COVID-19 testing during the 12-month long tudy.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COVID-19 Test Reporting
Description: Participants will use a simple text-based data reporting tool which they will be asked to use to report any COVID-19 testing during the 12-month long tudy.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Nudges via Text Messaging
Description: Weekly behavioral nudges via mobile phone text messages, personalized to participants' diabetes status, race/ethnicity, age group, sex, and/or vaccine/testing history, will be sent in weeks 1-16 of the intervention to encourage adherence to COVID-19 testing and preventive behaviors as well as other behaviors important for diabetes management, prevention, or care.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Non-personalized Nudges via Text Messaging
Description: Weekly behavioral nudges via mobile phone text messages will be sent in weeks 1-16 of the intervention sharing tips lifestyle behaviors important for diabetes management and prevention (e.g., exercise, eating a healthy diet, etc.).
Study: NCT05798247

Intervention type: OTHER
Intervention: Characteristics description
Description: Caregivers who follow the patients of the study group will be contacted to collect these patients clinical and epidemiological characteristics
Study: NCT05280184

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coin2Dose
Description: Behavioral Economics incentive intervention that also combines automated text message reminders to dose for insulin
Study: NCT04770571

Intervention type: DEVICE
Intervention: observational study
Description: observational

Intervention type: DEVICE
Intervention: observational study
Description: observational
Study: NCT05882877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocatinlimab
Description: Subcutaneous (SC) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocatinlimab
Description: Subcutaneous (SC) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocatinlimab
Description: Subcutaneous (SC) injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: SC injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: SC injection
Study: NCT06193174

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C134 Re-Administration
Description: Administration of a second dose of C134 to participants that have completed the study Trial of C134 in Patients With Recurrent GBM (C134-HSV-1).
Study: NCT05812859

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vaginal Orthosis (COSM Medical)
Description: A vaginal orthosis will be 3-D printed by COSM Medical and provided for patients to use from week 2 through week 12 post-operatively. Device will be placed in morning and removed before bed daily.
Study: NCT06564909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-Carnitine
Description: L-Carnitine 5 g intravenous administered as slow IV push over 2-3 minutes (L-Carnitine 1 gm / 5 mL Injection®, MEPACO, Egypt) and Carnitol 500 mg® Oral, Global Napi, Egypt)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: The standard care for the management of myocardial infarction post PCI
Description: include the required antiplatelet (Dual Antiplatelet Therapy; DAPT), anticoagulants, and anti-ischemic measures (high-intensity statin, ACEI, or aldosterone) as per latest guidelines recommendations.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: The standard care for the management of myocardial infarction post PCI
Description: include the required antiplatelet (Dual Antiplatelet Therapy; DAPT), anticoagulants, and anti-ischemic measures (high-intensity statin, ACEI, or aldosterone) as per latest guidelines recommendations.
Study: NCT06349408

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI3001
Description: The provisional dose levels are planned to be evaluated, but it is possible for additional and/or intermediate dose levels to be added during the study.~IBI3001 is proposed to be administered by intravenous infusion (IV)
Study: NCT04770584

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fear Conditioning
Description: Participants will be administered increasing intensities of mild electric shock via electrodes connected to the foot. New Biopac stimulators that can deliver higher shock intensity, provided participants agreement will be used to assure adequate conditioning levels. Stimulation is measures in milliamps (mA), and each delivered stimulation will be 0.5 seconds long (500 milliseconds). To colored (blue, red, \& yellow) light stimuli (CS). The light stimulus is followed by a shock or no shock depending on color.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Avoidance conditioning
Description: Via button pressing. Only one stimulus-CS will enable control over experiencing the shock: the participant can press the button during the first 2 seconds of the light presentation to avoid the shock.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pavlovian fear extinction learning
Description: After avoidance conditioning, the CS+ associated with avoidance responding appears with no button to press and no shock is administered.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Willingness to pay to avoid shock
Description: On the next day, participants receive a monetary stipend to use to pay to guarantee that they are not to receive any shocks if they press a button from the CS+. This and all previously described experimental phases noted above will occur inside of the fMRI scanner.
Study: NCT06215027

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dance
Description: Dance protocol
Study: NCT05867433

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STHS Intervention
Description: STHS program~The intervention group (10 schools) will participate in the STHS program. During the fall semester (September to December), the intervention group will receive 24 thirty-minute modules (or twelve 1-hour modules) that provide education on civic engagement, healthy eating, and physical activity. During the spring semester (February to May), the intervention group will receive 24 thirty-minute modules (or twelve 1-hour modules) that focus on implementing the school health environmental change project and receive support for maintaining individual-level healthy eating and physical activity behaviors.
Study: NCT05559931

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N,N-Dimethyltryptamine
Description: IV infusion over 6 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N,N-Dimethyltryptamine
Description: IV infusion over 6 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo infusion over 6 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo infusion over 6 hours
Study: NCT05166785

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: DPP Tailored for Older Adults and delivered via Telehealth
Description: Diabetes Prevention Program (DPP) Tailored for Older Adults and delivered via Telehealth (DPP-TOAT) will be composed of 16 60-minute weekly sessions followed by six 60-minute monthly support sessions

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: In-Person Diabetes Prevention Program (DPP)
Description: Diabetes Prevention Program (DPP) is composed of 16 60-minute weekly sessions followed by six 60-minute monthly support sessions over 12 months in person approved by the Centers for Disease Control and Prevention (CDC)
Study: NCT05921344

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multi-channel Microspatial Offset Raman Scattering Spectroscopy (mμSORS) for Noninvasive Blood Glucose Detection
Description: Blood glucose of participants were measured by venous plasma and multi-channel microspatial offset Raman scattering spectroscopy (mμSORS). The two measurements were collected synchronously and analyzed.